Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Huang, Xiaojun  [Clear All Filters]
2024
Hu L, Li Z, Yang S, Zhao T, Duan W, Qin Y, Jia J, Wang J, Lu S, Jiang H, et al. Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia. Ann Hematol. 2024.
Fan S, Mo X, Zhang X, Xu L, Wang Y, Yan C, Chen H, Zhang Y, Cheng Y, Sun Y, et al. Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study. Ann Hematol. 2024.
Tang F, Wang Y, Wang Y, Jin J, Han W, Chen Y, Yan C, Xu L, Zhang X, Huang X. The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome. Clin Exp Med. 2024;24(1):33.
Fu H, Cai X, Cui L, Nong W, Li W, Mei H, Yang T, Yue H, Huang Q, An Z, et al. The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset: A nationally representative, prospective, multicentre, observational study. Ann Hematol. 2024.
Fu H, Sun X, Lin R, Wang Y, Xuan L, Yao H, Zhang Y, Mo X, Lv M, Zheng F, et al. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. BMC Med. 2024;22(1):85.
Shang Q, Bai L, Cheng Y, Suo P, Hu G, Yan C, Wang Y, Zhang X, Xu L, Liu K, et al. Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia. Bone Marrow Transplant. 2024.
Xiao M, Zhou J, Zhu X, He Y, Wang F, Zhang Y, Mo X, Han W, Wang J, Wang Y, et al. A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024.
Pan X'an, Chang Y, Ruan G, Zhou S, Jiang H, Jiang Q, Huang X, Zhao X-S. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clin Exp Med. 2024;24(1):35.
2023
Li Y, Wang Y, Wang Z, Feng L, Gao L, Shi Y, Dang H, He Q, Qin Y, Jiang Q, et al. [Analysis of the characteristics of primary acute myeloid leukemia with 11q23/KMT2A rearrangements in ninety patients]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023;40(12):1472-1477.
Wang Z, Wang Y, Song W, Feng L, Gao L, Li Y, Huang X, Lai Y. [Application of fluorescence in situ hybridization technique to verify the clonalities of non-clonal cytogenetic abnormalities identified in Myelodysplastic syndrome]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023;40(3):257-262.
Zhao X, Wu H, Cheng Y, Xu Z, Chen Y, Chang Y, Wang Y, Zhang X, Xu L, Huang X. Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia. Chin Med J (Engl). 2023.
Sun W, Zhang Y, Chen Y, Sun Y, Cheng Y, Wang F, Chen H, Chen Y, Yan C, Mo X, et al. Comparison of clinical features of nephrotic syndrome after haploidentical and matched donor hematopoietic stem cell transplantation. Chin Med J (Engl). 2023.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Zhu X, Jiang Q, Lu J, Sun Y, Zhao X, Yang S, Tang F, Yu W, Zhao T, Liu X, et al. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China. Br J Haematol. 2023.
Zhao X, Lin M, Huang X. Current status and future perspective of natural killer cell therapy for cancer. Med Rev (2021). 2023;3(4):305-320.
Tang F, Zhao X, Ruan G, Jiang Q, Jiang H, Xu L, Wang Y, Zhang X, Liu K, Huang X. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation. Hematol Oncol. 2023.
Qi F, Zhang X, Gale RPeter, Liu B, Huang J, Huang X, Jiang Q. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy. Leukemia. 2023.
Zhou C, Zheng F, Xu L, Zhang X, Chang Y, Mo X, Sun Y, Huang X, Wang Y. The FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in AML patients with FLT3-ITD after allo-HSCT: a retrospective propensity-score matching study. Transplant Cell Ther. 2023.
Huang X, Su X, Ma Q, Xie Y, Guo Q, Liao L, Zou J. FoxO1 agonists promote bone regeneration in periodontitis by protecting the osteogenesis of periodontal ligament stem cells. Stem Cells Dev. 2023.
Zeng M, Xia J, Zong Z, Shi Y, Ni Y, Hu F, Chen Y, Zhuo C, Hu B, Lv X, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect. 2023.
Cao X, Huang X, Zhao X. Immune-related genetic prognostic index to predict prognosis and immune checkpoint inhibitor therapy efficiency in acute myeloid leukemia. Chin Med J (Engl). 2023.
Ma X, Xu Z, Han T, Zhang Y, Han W, Fu H, Zhang X, Lin F, Huang X, Xu L. Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients. Front Immunol. 2023;14:1173320.
Chen Y, Huang X, Qiu H, Cheng L, Yu Y, Ma X, Feng S, Li Q, Wu D, Huang W, et al. Physicians' knowledge of invasive fungal disease in China. Mycoses. 2023.
Pan X'an, Chang Y, Ruan G, Wei F, Jiang H, Jiang Q, Huang X, Zhao X. Prognostic impact of FLT3-ITD mutation on NPM1 acute myeloid leukaemia patients and related molecular mechanisms. Br J Haematol. 2023.
Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, Chi P, Xu Y, Xu N, Deng L, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023.

Pages